Home・Lista de Ações・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Fechado

3.86 0.78

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

3.74

Máximo

3.88

Indicadores-chave
By Trading Economics
Rendimento	-42M -78M
EPS	-0.59
Funcionários	106
EBITDA	-42M -77M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+134.84% upside

Dividendos
By Acuity
Próximos Ganhos	6 de nov. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	25M 356M
Abertura anterior	3.08
Fecho anterior	3.86

Zentalis Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

25 de ago. de 2026, 23:56 UTC

Correlated Moves

Emerson Electric Co's shares are lower in after-market hours, reflecting a decline since Tuesday's close amid broader market sentiment influencing the stock's movement.

25 de ago. de 2026, 23:56 UTC

Charles River Laboratories shares are higher in after-market trading, maintaining a position near the upper end of their one-month range amid lower crude oil prices.

25 de ago. de 2026, 23:56 UTC

Host Hotels and Resorts, Inc. shares are lower in after-market hours. No specific news was identified to explain the decline, amid falling crude oil prices.

25 de ago. de 2026, 23:56 UTC

Correlated Moves

KKR & Co Inc shares are lower in after-market hours, reflecting broader trends in the financial sector amid minimal change since Tuesday's close.

25 de ago. de 2026, 23:56 UTC

ETF Constituents

Correlated Moves

Vanguard Morningstar Mid-Cap ETF trades higher after-market, supported by contributions from HWM, PWR, VST, NET, and LHX amid a rising Russell 2000 Index.

25 de ago. de 2026, 23:56 UTC

Correlated Moves

M&T Bank Corp shares are lower in after-market trading, influenced by a decline in Wells Fargo and broader market sentiment affecting the banking sector.

25 de ago. de 2026, 23:56 UTC

Allogene Therapeutics Inc. is trading roughly flat in after-market hours, maintaining a position near the upper end of its one-month range.

25 de ago. de 2026, 23:56 UTC

Correlated Moves

NiSource Inc shares are trading lower in after-market hours, influenced by a decline in Sempra and broader market sentiments affecting utility stocks.

25 de ago. de 2026, 23:56 UTC

Toast Inc shares are higher in after-market trading, maintaining a position above the 20-day moving average and near the upper end of their one-month range.

25 de ago. de 2026, 23:56 UTC

Baker Hughes Co's shares are higher in after-market trading, with no specific news identified. Broader market trends may be influencing positive sentiment.

25 de ago. de 2026, 23:56 UTC

Correlated Moves

Johnson Controls International PLC shares rose in after-market trading, reflecting modest gains amid favorable investor sentiment and a correlation with nVent Electric PLC.

25 de ago. de 2026, 23:56 UTC

Correlated Moves

Public Service Enterprise Group Inc. sees modest gains in after-market trading, aligning with broader trends from related companies like DTE Energy Co.

25 de ago. de 2026, 23:56 UTC

Correlated Moves

Shares of APA Corp declined in after-market trading, continuing a trend of lower daily finishes, amid falling WTI crude oil prices.

25 de ago. de 2026, 23:56 UTC

Fidelity National Information Services shares are trading lower in after-market hours. The asset remains below its 20-day moving average.

25 de ago. de 2026, 23:56 UTC

Williams Companies Inc. shares are higher in after-market trading, reflecting a slight gain since Tuesday's close amid declining crude oil prices and lower treasury yields.

25 de ago. de 2026, 23:56 UTC

Diamondback Energy shares traded roughly flat in after-market hours, following four consecutive sessions of declines amid lower crude oil prices and treasury yields.

25 de ago. de 2026, 23:56 UTC

Correlated Moves

Fifth Third Bancorp remains roughly flat in after-market trading, despite a slight increase in the Dow Jones Index and declining crude oil prices.

25 de ago. de 2026, 23:56 UTC

Correlated Moves

Jones Lang LaSalle Inc shares are lower in after-market trading, reflecting a broader decline in the real estate sector alongside Marcus & Millichap Inc.

25 de ago. de 2026, 23:52 UTC

Mexico's Business Confidence Remains Low at 48.0 Ahead of Key Survey Amid Mixed Trade Sentiments with the U.S.

25 de ago. de 2026, 23:52 UTC

Brazil's Q2 2026 GDP Growth Rate Release Looms Amid Declining Consumer Confidence and Cautious Market Sentiment.

25 de ago. de 2026, 23:52 UTC

Brazil's Q2 2026 GDP growth release on September 1 expected to reflect strong government spending amid mixed consumer confidence and rising inflation concerns.

25 de ago. de 2026, 23:52 UTC

India's Current Account Balance Release on September 1, 2026 Expected to Impact Market Sentiment Amid Rising Import Costs and Geopolitical Pressures.

25 de ago. de 2026, 23:52 UTC

Brazil's Central Bank to Announce SELIC Rate Decision Amid Global Monetary Policy Uncertainty on August 31, 2026.

25 de ago. de 2026, 23:52 UTC

Social Media

Warner Bros Discovery Inc shares traded lower in after-market hours amid ongoing scrutiny in the antitrust case involving Paramount and related legal developments.

25 de ago. de 2026, 23:52 UTC

UniFirst Corp shares declined in after-market trading, despite a favorable macro environment with falling crude oil prices and lower Treasury yields.

25 de ago. de 2026, 23:51 UTC

DraftKings shares are higher in after-market trading amid favorable market conditions and a decline in crude oil prices. No specific news was identified.

25 de ago. de 2026, 23:51 UTC

Travel + Leisure Co shares are higher in after-market hours. No specific company news was identified, but declining crude oil prices may be influencing sentiment.

25 de ago. de 2026, 23:51 UTC

Correlated Moves

American Water Works shares are higher in after-market trading, supported by a decline in crude oil prices and easing inflation concerns.

25 de ago. de 2026, 23:51 UTC

Asia equity markets mixed as investors react to geopolitical tensions, falling crude oil prices, and await key U.S. economic data releases.

25 de ago. de 2026, 23:51 UTC

Mixed trading in Europe as Germany's Ifo index rises, while France's consumer confidence dips; U.S. markets gain on falling oil prices and tech stock rallies ahead of key earnings.

Comparação entre Pares

Variação de preço

Zentalis Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

134.84% parte superior

Previsão para 12 meses

Média 8.83 USD 134.84%

Máximo 11 USD

Mínimo 5 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Zentalis Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

6 ratings

Comprar

Manter

Vender

Com base em 6 analistas que deram avaliações de ações para Zentalis Pharmaceuticals Inc - Dist nos últimos 3 meses.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.